$0.29
-0.03 (-9.35%)
Open$0.32
Previous Close$0.32
Day High$0.32
Day Low$0.28
52W High$0.86
52W Low$0.16
Volume—
Avg Volume3.09M
Market Cap14.16M
P/E Ratio—
EPS$-4.01
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+13,209.3% upside
Current
$0.29
$0.29
Target
$38.73
$38.73
$26.34
$38.73 avg
$46.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.08M | 955.9K |
| Net Income | -22,361 | -31,787 | -25,174 |
| Profit Margin | -2.2% | -2.9% | -2.6% |
| EBITDA | -38,355 | -35,389 | -33,870 |
| Free Cash Flow | -18,843 | -19,077 | -22,857 |
| Rev Growth | +0.6% | -3.8% | +4.7% |
| Debt/Equity | 0.84 | 0.93 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |